A phase I/II study of IMGN632, a novel CD123-targeting antibody-drug conjugate, in patients with relapsed/refractory acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm, and other CD123-positive hematologic malignancies.

Affiliation auteurs!!!! Error affiliation !!!!
TitreA phase I/II study of IMGN632, a novel CD123-targeting antibody-drug conjugate, in patients with relapsed/refractory acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm, and other CD123-positive hematologic malignancies.
Type de publicationJournal Article
Year of Publication2020
AuteursDaver NGuastad, Montesinos P, DeAngelo DJ, Wang ES, Todisco E, Tarella C, Martinelli G, Erba HPaul, Deconinck E, Sweet KL, Walter RB, Levy MYair, Pemmaraju N, Lane AA, Rizzieri D, Konopleva M, Sloss CMortimer, Wang J, Malcolm KE, Zweidler-McKay PA
JournalJOURNAL OF CLINICAL ONCOLOGY
Volume38
Date PublishedMAY 20
Type of ArticleMeeting Abstract
ISSN0732-183X